Financings
• Alexza Pharmaceuticals Inc. is raising $18 million in a registered direct offering of stock and warrants.
• Cardioxyl Pharmaceuticals Inc. raised $15 million in venture funding.
• Complete Genomics Inc. filed to raise $86 million in an initial public offering.
• Horizon Pharma Inc. filed to raise $86 million in an initial public offering.
• Idera Pharmaceuticals Inc. is raising $15 million in a registered direct offering of stock and warrants.
• Trius Therapeutics Inc. raised $50 million in its initial public offering.
Deals
• Amplimmune Inc. signed a $508 million deal with GlaxoSmithKline plc for a preclinical cancer and infectious disease program.
• BrainCells Inc. is acquiring Proximagen Group plc's depression drug sabcomeline for $51 million.
• FivePrime Therapeutics Inc. signed a $139 million discovery deal with GlaxoSmithKline plc.
• Lexicon Pharmaceuticals Inc. repurchased its joint venture from Symphony Capital LLC.
• MiddleBrook Pharmaceuticals Inc. sold its assets to Victory Pharma Inc. for about $17.3 million in cash.
• Movetis NV attracted a $564.6 million all-cash takeover bid from Shire plc.
• Pfizer Inc. spun out subsidiary Idun Pharmaceuticals Inc. to Conatus Pharmaceuticals Inc. (no terms).
• Seattle Genetics Inc. signed a $912 million antibody-drug conjugate platform deal with Genentech Inc./Roche AG.
• Targacept Inc. signed a potential $75 million NNR patent deal with Cornerstone Therapeutics Inc.
. . . And More
• Cypress Bioscience, Inc. and Forest Laboratories Inc. discontinued their copromotion deal for fibromyalgia drug Savella, and Cypress cut 86 percent of its employees.
• Elusys Therapeutics Inc. won another year's worth of government funding for anthrax drug Anthin, valued at $40.6 million.
• Genzyme Corp. faced more manufacturing fallout as patients sought to invalidate its Fabrazyme (agalsidase beta) patents.
• Geron Corp. restarted its Phase I human embryonic stem cell trial, which the FDA took off hold.
• Isis Pharmaceuticals Inc. and Genzyme Corp. said mipomersen lowered cholesterol in two Phase III resistant hypertension studies.
• Lux Biosciences Inc.'s ophthalmic drug Luveniq got rejected by the FDA, which requested more trials.
• NicOx SA is closing its U.S. headquarters in the wake of an FDA rejection of osteoarthritis drug naproxcinod.
• Vertex Pharmaceuticals Inc.'s hepatitis C protease inhibitor telaprevir got plenty of comparison to Merck & Co. Inc.'s boceprevir, which reported Phase III data.